Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Kadmon Holdings, Inc. | kdmn-20161206xex99_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 6, 2016
Kadmon Holdings, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
001-37841 |
27-3576929 |
||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
||
|
450 East 29th Street New York, NY |
10016 |
|||
|
(Address of principal executive offices) |
(Zip Code) |
|||
Registrant’s telephone number, including area code (212) 308-6000
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
ITEM 8.01 |
Other Events. |
On December 6, 2016, Kadmon Holdings, Inc. (the “Company”) issued a press release announcing encouraging data from its ongoing Phase 2 clinical study of tesevatinib, the Company’s blood-brain barrier penetrant oral tyrosine kinase inhibitor, for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer that has metastasized to the brain and/or the leptomeninges (membranes lining the brain and spinal cord). The data were presented today in a poster session at the International Association for the Study of Lung Cancer 17th World Conference on Lung Cancer in Vienna, Austria. The full text of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
|
ITEM 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
|
|
|
|
99.1 |
Press Release, dated December 6, 2016, issued by Kadmon Holdings, Inc. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Kadmon Holdings, Inc. |
||||
|
Date: December 6, 2016 |
/s/ Konstantin Poukalov |
|||
|
Konstantin Poukalov |
||||
|
Executive Vice President, Chief Financial Officer |
||||